Clinical Trials Logo

Head and Neck Cancer clinical trials

View clinical trials related to Head and Neck Cancer.

Filter by:

NCT ID: NCT00114153 Completed - Clinical trials for Head and Neck Cancer

Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Start date: June 2003
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when given together with carboplatin followed by radiation therapy in treating patients with stage III or stage IV head and neck cancer.

NCT ID: NCT00113347 Completed - Clinical trials for Head and Neck Cancer

Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Start date: April 2005
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest safe dose of the drugs OSI-774 and docetaxel that can be given together along with radiation treatment for advanced head and neck cancer.

NCT ID: NCT00113334 Completed - Clinical trials for Head and Neck Cancer

Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer

Start date: April 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The goals of this clinical research study are to see how individuals with advanced head and neck cancer respond to treatment with the new drug thrombospondin (ABT-510) and to learn how effective it is in destroying cancer cells. The safety of ABT-510 and the effect ABT-510 has on cells in the body will also be studied.

NCT ID: NCT00101335 Completed - Clinical trials for Head and Neck Cancer

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Start date: November 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of celecoxib may prevent or treat head and neck cancer. PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to placebo in preventing head and neck cancer in patients with oral leukoplakia.

NCT ID: NCT00100789 Completed - Clinical trials for Head and Neck Cancer

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Start date: January 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine together with paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with paclitaxel works in treating patients with persistent, recurrent, or metastatic head and neck cancer.

NCT ID: NCT00099021 Completed - Clinical trials for Head and Neck Cancer

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Start date: June 2003
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pioglitazone hydrochloride works in preventing head and neck cancer in patients who have oral leukoplakia. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of pioglitazone hydrochloride may be effective in preventing head and neck cancer.

NCT ID: NCT00098943 Completed - Colorectal Cancer Clinical Trials

NGR-TNF in Treating Patients With Advanced Solid Tumors

Start date: September 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Targeted therapy with tumor necrosis factor combined with a fusion protein may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of NGR-TNF in treating patients with advanced solid tumors.

NCT ID: NCT00096707 Completed - Breast Cancer Clinical Trials

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

Start date: February 2004
Phase: Phase 1
Study type: Interventional

The objectives of this study are to evaluate the safety, tolerability, pharmacokinetics, and biologic effect (FDG PET, preliminary efficacy) of daily oral doses of 2DG with and without weekly docetaxel in subjects with advanced solid tumors.

NCT ID: NCT00096174 Completed - Clinical trials for Head and Neck Cancer

Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck

Start date: April 8, 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cetuximab may make the tumor cells more sensitive to radiation therapy and chemotherapy. Giving monoclonal antibody therapy together with chemoradiotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab and cisplatin together with radiation therapy works in treating patients with locally advanced or regional stage IV head and neck cancer that cannot be removed by surgery.

NCT ID: NCT00095927 Completed - Clinical trials for Head and Neck Cancer

Randomized Amifostine For SCCHN

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.